NCT00615524 2018-01-12Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast CancerGlaxoSmithKlinePhase 2 Withdrawn
NCT00347919 2016-02-25Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast CancerGlaxoSmithKlinePhase 2 Completed189 enrolled 15 charts